# US 2025/0144244 A1 · Treatment of acquired focal epilepsy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144244 A1
- Document ID: US20250144244A1
- Status: Published application
- Kind: A1
- Application number: 18/837,652
- Filed: 2023-02-10
- Published: 2025-05-08
- Earliest claimed: 2022-02-10
- Applicants: Ucl Business Ltd
- Inventors: Matthew Charles WALKER; Gabriele LIGNANI; Dimitri M. KULLMANN; Eleanora LUGARÀ; Marta PEREZ GONZALEZ; Stephanie SCHORGE; Albert SNOWBALL; Jenna CARPENTER; Elodie CHABROL-PIPARD
- Web page: https://patentgrep.com/patent/US20250144244A1

## CPC

- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- A61K 9/0085: {Brain, e.g. brain implants; Spinal cord}
- A61K 38/1709: {from mammals}
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- A61P 25/08: Antiepileptics; Anticonvulsants
- C12N 15/86: Viral vectors
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14152: relating to complementing cells and packaging systems for producing virus or viral particles
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention provides methods of treatment of acquired focal epilepsy in a human subject in need of the same, the methods comprising: (i) providing an expression vector encoding a polynucleotide sequence encoding LGI1, wherein the polynucleotide sequence is operably linked to a promoter suitable to drive expression of the LGI1 in human cells, (ii) administering the expression vector to the subject. Overexpressing LGI1 has been shown to affect excitatory neurons beyond the area of expression thereby targeting a large area and affecting neurons in an advantageously uniform manner.

## Claims

### Claim 1

A method of treatment of acquired focal epilepsy in a human subject in need of the same, the method comprising:
(i) providing an expression vector encoding a polynucleotide sequence encoding LGI1, wherein the polynucleotide sequence is operably linked to a promoter suitable to drive expression of the LGI1 in human cells,
(ii) administering the expression vector to the subject.

### Claim 2 (depends on 1)

The method as claimed in claim 1 wherein the polynucleotide sequence encoding LGI1 encodes an amino acid sequence comprising or consisting the amino acid sequence shown in SEQ ID NO: 2 or a homologous variant thereof.

### Claim 3 (depends on 2)

The method as claimed in claim 2 wherein the polynucleotide sequence encoding LGI1 has a nucleotide sequence comprising or consisting of the nucleotide sequence shown in SEQ ID NO: 1 or a homologous variant thereof, which is optionally a codon optimised sequence, which is optionally shown in SEQ ID NO: 3.

### Claim 4 (depends on 1, 2, 3)

The method as claimed in any one of claims 1 to 3 wherein the promoter is a cell type specific promoter.

### Claim 5 (depends on 4)

The method as claimed in claim 4 wherein the cell type specific promoter is specific for neurons.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method as claimed in any one of claims 1 to 5 wherein the promoter is a CAG promoter or human synapsin promoter.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method as claimed in any one of claims 1 to 6 wherein the vector is a viral vector.

### Claim 8 (depends on 7)

The method as claimed in claim 7 wherein the vector is an AAV vector.

### Claim 9 (depends on 8)

The method as claimed in claim 8 wherein the AAV vector is an AAV9 vector, optionally an AAV2/9 vector.

### Claim 10 (depends on 7, 8)

The method as claimed in claim 7 or claim 8 wherein the vector has the nucleotide sequence of SEQ ID NO: 4 or a homologous variant thereof, optionally lacking the GFP sequence.

### Claim 11 (depends on 7, 8, 9, 10)

The method as claimed in any one of claims 7 to 10 which comprises the steps of:
(i) assembling viral particles in vitro by transducing mammalian cells with the expression vector and expressing viral packaging and envelope proteins necessary for particle formation in the cells and culturing the transduced cells in a culture medium, such that the cells produce viral particles comprising the expression vector that are released into the medium;
(ii) administering the viral particles to the subject.

### Claim 12 (depends on 11)

The method of claim 11, wherein the method comprises transducing the mammalian cells with one or more viral packaging and envelope expression vectors that encode the viral packaging and envelope proteins necessary for particle formation.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method as claimed in any one of claims 1 to 12 wherein the expression vector or viral particles comprising the expression vector are administered directly to a CNS site in the subject.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method as claimed in any one of claims 1 to 13 wherein the acquired focal epilepsy affects a single area of the brain.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method as claimed in any one of claims 1 to 13 wherein the acquired focal epilepsy affects multiple discrete areas of the brain.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method as claimed in any one of claims 1 to 15 wherein the acquired focal epilepsy is temporal lobe epilepsy with hippocampal sclerosis.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

An expression vector or viral particle comprising an expression vector for use in a method of treatment of acquired focal epilepsy in a human subject as claimed in any one of claims 1 to 16.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A method of treatment of acquired focal epilepsy in a human subject comprising use of an expression vector or viral particle comprising an expression vector as defined in any one of claims 1 to 16.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

Use of an expression vector or use of a viral particle comprising an expression vector as defined in any one of claims 1 to 16 in the manufacture of a medicament for the treatment of acquired focal epilepsy in a human subject.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

Use of an expression vector or use of a viral particle comprising an expression vector in the manufacture of a medicament for the treatment of acquired focal epilepsy in a human subject, wherein the treatment is as claimed in any one of claims 1 to 16.
